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INTRODUCTION 
Non-melanoma skin cancer 
Non-melanoma skin cancer (NMSC) is the most prevalent cancer today impacting more 
people than all other cancers combined with an estimated 2-3 million new cases a year 
in the United States (ACS 2014, Rogers et al 2010). Because NMSC tends not to be life 
threatening, less attention has been paid to this type of cancer. Unfortunately, having 
NMSC does have consequences. Lesions tend to appear in areas exposed to the sun and 
to the sight of others (Haynes 1991). Currently the most common form of treatment is 
reductive surgery which can be disfiguring especially on the face and head (Neville et al 
2007). A greater understanding on how NMSC is initiated and progresses is needed to 
prevent and treat future cases.  
Ultraviolet light: the inducer of NMSC 
Exposure to sunlight specifically ultraviolet (UV)radiation is the major environmental risk 
factor for developing NMSC (Clingen et al 1995, Fuchs & Raghavan 2002, Kripke 1993, 
Mullenders et al 1997, Tyrrell 1994, Wikonkal & Brash 1999, Yuspa & Dlugosz 1991). UV 
is divided into 3 wavelength ranges: UVA (320-400nm), UVB (280-320 nm), and UVC 
(200-280 nm). UVC radiation, the shortest wave length, has the greatest potential to 
cause the most damage in skin. Fortunately nearly all UVC radiation is filtered out by the 
ozone layer and does not reach the earth’s surface. UVA, the most abundant UV 
radiation, penetrates through the skin’s outer layer, the epidermis, to the fibroblasts in 
the dermis where oxidative stress is induced.  Though not the most abundant, UVB is 
the primary cause of NMSC in spite of only penetrating into the epidermis and affecting 
keratinocytes.   The skin contains several targets of UVB such as DNA, trans-urocanic 
acid (UCA), and lipids. Photons of UVB are either directly absorbed by DNA, causing 
changes to its structure forming cyclobutane pyrimidine dimers (CPD) and 6-4 
photoproducts (6-4 PPs), or generate reactive oxygen species (ROS) that oxidize certain 
bases in the DNA in the skin (Ichihashi et al 2003, Mullenders et al 1997, Pfeifer et al 
2005). The DNA damage triggers the keratinocytes to respond in one of the following 
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ways: 1) undergo programmed cell death due to extensive DNA damage, 2) senesce 
continuing bio-chemical activities but do not proliferate, 3) repair the DNA damage and 
continuing proliferating, or 4) do not repair the damage and proliferate.  NMSC can arise 
if there is a disruption of the balance between proliferation and apoptosis. Lack of 
proper growth and cell cycle controls allow for increased numbers of damaged cells 
leading to tumors. 
 
Gender bias of NMSC 
Historically, men have a greater incidence of NMSC than women as shown 
observationally through population studies (Lewis & Weinstock 2007, Lomas et al 2012, 
Rogers et al 2010).  Men are two times more likely to develop basal cell carcinoma (BCC) 
and three times as likely to develop squamous cell carcinoma (SCC) than women (Holme 
et al 2000, Leiter & Garbe 2008). Initially, this disparity was attributed to men having 
outdoor occupations, thus being exposed to more sunlight (Armstrong & Kricker 2001, 
Gawkrodger 2004, Suarez et al 2007). This has not been proven to be the case. In 2007 
the lab of Dr. Tatiana Oberyszyn reported that male and female mice responded 
differently when exposed to the same amount of UV.  Female mice had fewer and 
smaller tumors that took longer to appear (Thomas-Ahner et al 2007). When exposing 
mice to a single high dose of UVB, they found that the female mice had a marked 
increase in skin fold thickness, described as a measure of inflammation.  Accompanying 
this phenotype was a three-fold increase in both myeloperoxidase and neutrophil 
infiltration in the female mice demonstrating more antioxidant activity. Conversely, 
male mice had higher levels of 8-oxo-dG, the DNA damage that results from oxidative 
stress. Ovariectomized female mice exhibited the same response as the male mice.  If 
exposure differences are not the cause, then what is the driver of this bias? Could there 
be a biochemical difference between men and women that accounts for the difference?  
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Estrogen and Estrogen Receptor 
Signaling through the estrogen receptor (ER) may be the key. Population studies have 
shown that many cancers are less prevalent in women such as lung cancer (Belani et al 
2007, Cerfolio et al 2006, Fu et al 2005, Henschke et al 2006, Moore et al 2004, 
Ouellette et al 1998, Radzikowska et al 2002, Shafer & Albain 2009), leukemia (Berger et 
al 2005, Deschler & Lubbert 2006, Xie et al 2003), hepatocellular carcinoma(Bosch et al 
2004), bladder cancer (Zhang 2013) and colorectal cancer (CRC)  (Brenner et al 2007, 
Gao et al 2008). Swedish postmenopausal women receiving hormone replacement 
therapy had a 40% decreased incidence of CRC, liver, and biliary cancer compared to 
women not receiving hormone replacement therapy (Persson et al 1996).  Estrogen 
signaling is not exclusive to women. Both genders express estrogen receptors and 
produce estrogen. 17β-estradiol, the most potent ligand also called E2, is produced in 
the adrenal glands, testis, and ovaries.  Women have more circulating estrogen than 
men which diminishes when menopause is reached. The most prevalent role estrogen 
and its receptor play are in signaling secondary sexual characteristics, but this is not the 
only role of estrogen receptors. Estrogen receptors are transcriptional regulators that 
bind directly to estrogen response elements, or indirectly to other promoter elements 
as part of a transcription factor complex to promote or repress expression of target 
genes.  In addition, the binding of E2 to the estrogen receptor can also initiate non-
genomic signal transduction in multiple pathways such as PI3K/AKT, MAPK, and SRC-
SHC-ERK where the resulting actions are tissue dependent. Growth factors can also 
phosphorylate the estrogen receptor causing activation and regulation of transcription 
in a non-ligand dependent manner (Zhou & Slingerland 2014).   
Estrogen Receptor Alpha (ERα) 
There are two different subtypes of estrogen receptor: alpha and beta. ERα was 
discovered by Dr. Elwood Jensen in the late 1950’s then cloned and sequenced from the 
MCF-7 breast cancer cell line in 1986 by Dr. Geoffrey L Greene (Greene et al 1986).  
Most of the research on estrogen receptors has been focused on the alpha subtype in 
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target tissues such as breast, ovary, and uterus where exposure to estrogen has been 
linked to hyper-proliferation and increased cancer risk.  ERα activates expression of myc 
and cyclin D1 to promote cell cycle transition from G1 to S, Bcl2 and BclXL to prevent 
apoptosis, and IL-8 and VEGF to stimulate angiogenesis in target tissues (Zhou & 
Slingerland 2014). Other genes are upregulated by E2 binding to ERα including but are 
not limited to IGF-1, collagenase, LDL-R, c-fos. Not all genes are activated by ERα for 
example choline acetyltransferase and IL-6 are repressed. ERα activity is context specific 
due to the combination of transcription cofactors needed and available in the 
microenvironment.  This receptor is more ubiquitous than once thought as it has also 
been found in many other tissues including prostate, testes, bone, brain, liver and white 
adipose tissue (Dahlman-Wright et al 2006).  
Estrogen Receptor Beta (ERβ) 
ERβ was identified and characterized in 1996. ERα and ERβ share   95% sequence 
homology in the DNA binding domain and  55% sequence homology in the ligand 
binding domain; they bind the same response elements, and have a similar affinity for 
estradiol though they are encoded by different genes on different chromosomes (Kuiper 
et al 1996, Mosselman et al 1996). The receptors differ significantly in the NH2 terminus, 
where the AF-1 domain which controls transcriptional activation by the receptor is 
located (Delaunay et al 2000). ERβ expression has been reported in many tissues such as 
colon, prostate, testes, ovary, bone, salivary glands, vascular endothelium, and brain 
(Dahlman-Wright et al 2006). The function of ERβ is still being elucidated but what has 
been shown is that ERβ acts differently than ERα. For example, both receptors modulate 
cyclin D1 when bound to E2 with alpha increasing expression and beta repressing 
expression. Yet when exposed to anti-estrogens, both activated receptors induced cyclin 
D1 expression (Liu et al 2002). Thus, ERβ may be acting to prevent tumor induction and 
to oppose the proliferative effects of ERα especially in the non-target tissues.  
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Estrogen Receptors in Skin 
The literature is conflicting regarding the presence of ERα and ERβ receptors in skin. 
ERα was first isolated from skin homogenates and characterized in 1980 (Hasselquist et 
al 1980, Punnonen et al 1980). In male and female scalp samples, Thornton et al 
reported ERα was not present in the epidermis but was expressed in the sebaceous 
glands with ERβ expressed in the epidermis notably in the basal layer, sebaceous glands, 
and dermal fibroblasts.  (Thornton et al 2003).  These results were confirmed and ERβ 
expression was also noted in the bulge/follicle region along with sweat glands (Pelletier 
& Ren 2004). Verdier-Severain had contradictory data showing both ER α and β 
expression in keratinocytes (Verdier-Sevrain et al 2004). In addition,  the data on the 
response to keratinocytes in culture to E2 is not consistent with some groups reporting 
increased proliferation in neonatal (Verdier-Sevrain et al 2004) and adult cells (Urano et 
al 1995), but not in female post-menopausal cultures (Tammi 1982).  In menopausal 
women, hormone replacement therapy, either estrogen or estrogen-progesterone did 
not change the rate of NMSC compared to the placebo control (Tang et al 2011). With 
the historic epidemiology data and the unclear role of ER in skin, we hypothesize that E2 
may play a protective role in UVB-induced skin cancer.  
The Hypothesis 
Female mice in the Thomas-Ahner study (Thomas-Ahner et al 2007) had a greater ability 
to prevent DNA damage due to oxidative stress, but this protection from initiating 
mutations is merely one facet of the development of cancer. In Hanahan and 
Weinburg’s seminal papers in Cell, the pair discusses the multiple axis  that contribute 
to and foster cancer which include: resisting cell death, sustaining proliferative signaling, 
evading growth suppressors, inducing angiogenesis, enabling replicative immortality, 
activating invasion and metastasis, deregulating cellular energetics and avoiding 
immune destruction (Hanahan & Weinberg 2000, Hanahan & Weinberg 2011). E2 
signaling through the estrogen receptor could have the potential to influence any of 
these hallmarks. We will focus our attention to resisting cell death and sustaining 
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proliferation as these are the mechanisms that lead to cancerous growth and the ability 
of cancer to escape regulation of genetic editing. This allows pre-neoplastic and 
neoplastic cells the opportunity to accumulate and perpetuate genetic lesions. Balance 
between proliferation, apoptosis, and senescence is of the utmost importance in skin to 
maintain the integrity of the barrier function.  
To explore the hypothesis, we utilized two skin cell models, normal human foreskin 
keratinocytes (NHK) and nTERT immortalized neonatal male keratinocytes, with 
endogenous expression of ERα and ERβ. Metastatic breast cancer cell lines, MCF-7 and 
MDA-MB-231 were used as the positive and negative controls for estrogen receptor 
alpha, respectively.  Due to the ambiguous literature, we determined the presence of 
ERα and ERβ mRNA and protein along with subcellular localization in the cell models 
along with tissue isolates from epidermis and dermis.  We wanted to examine if E2 -
treatment had any effect on keratinocytes to respond appropriately to UVB exposure. 
Proliferation was assessed by cell counts after E2-treatment and UVB exposure. Caspase- 
3 activity was used to measure UVB induced apoptosis via both the intrinsic and 
extrinsic pathways. Cells that senesce retain the barrier function of the skin but are still 
biologically active and contribute to the surrounding microenvironment. Senescence 
activated beta-galactosidase assays were used to determine if E2-treatment increased 
UVB-induced senescence. Activated IGF1R and intact p53 were needed for senescence 
to occur in keratinocytes.  Interestingly, keratinocytes do not produce IGF1. They rely on 
fibroblasts to produce and secrete the IGF1 ligand into the skin.  IGF1 is a known target 
gene of estrogen in other tissues. E2 in fibroblasts could stimulate IGF1 production to 
induce senescence in keratinocytes. We examined the effect of E2-treatment on 
fibroblasts by using their conditioned media to treat keratinocytes prior to UVB 
irradiation to see the effect on apoptosis by measuring the activity of caspase 3.  
The signaling mechanisms involved in UVB-induced skin cancer are complex and 
although the scope of this work is inherently limited in focus, the findings may provide 
insight into how estrogen receptor signaling impacts cell growth, senescence, and 
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apoptosis to protect keratinocytes. Additional signaling due to E2-activation of the 
estrogen receptor may provide back-up or redundant pathways in response to UVB.    
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MATERIALS AND METHODS 
Cell Culture 
Normal human keratinocytes (NHK) and normal human fibroblasts (NHF) were isolated 
from neonatal foreskin tissue that was discarded following elective circumcision. The 
foreskin tissue was washed with Penicillin/Streptomycin/Amphotericin B and minced to 
allow for release of the individual cells using trypsin digestion. Cells were plated on 
serum-coated plastic dishes. Keratinocytes and fibroblasts were separated by 
differential resistance to treatment with EDTA (Kuhn et al 1999).  NHK cells were 
cultured in EpiLife media (Life Technologies, Portland, OR) supplemented with HKGS 
(human keratinocyte growth supplement (Life Technologies)) to a final concentration of 
0.2% bovine pituitary extract, 5 µg/mL bovine insulin; 0.18 µg/mL hydrocortisone, 5 
µg/mL bovine transferrin, and 0.2 ng/mL human epidermal growth factor (EGF)) and 
1000 U penicillin-streptomycin (Roche Molecular Biochemicals, Indianapolis, IN) 
subsequently referred to as complete media. NHF cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% calf serum. nTERT cells obtained from 
Dr. James Rheinwald, Harvard University (Dickson et al 2000), immortalized 
keratinocytes with increased telomerase activity and a loss of p16INK, were also cultured 
in EpiLife complete media. MCF-7 and MDA-MB-231 breast adenocarcinoma cell lines 
obtained from Dr. Harikrishna Nakshatri (Indiana University School of Medicine) were 
grown in DMEM supplemented with 10% fetal calf serum. All cell lines were cultured at 
37°C with 5% CO2. 17β-estradiol (E2, E2758, Sigma-Aldrich, St. Louis, MO) was diluted in 
100% ethanol to 10 nM or 1 nM. The stock was diluted 1:1000 in complete or growth 
factor deprived (GFD) media for the treatment experiments.  
Ultraviolet-B (UVB) irradiation 
Cells were irradiated with UVB light using 2 Philips (Andover, MA, USA) F20T12/UV 
sources as previously described (Cotton & Spandau 1997, Lewis et al 2003a, Lewis et al 
2003b). Prior to each experiment, the intensity of the UVB source was measured using 
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an IL1700 radiometer and a SED240 UVB detector (International Light, Newburyport, 
MA, USA) at 8 cm, equivalent to the distance between the UVB source and the cell 
monolayer. Cells were irradiated in EpiLife media and returned to standard incubation 
conditions. EpiLife medium filters out the UVC wavelengths without absorbing 
significant amounts of UVB wavelengths.  
qRT-PCR 
Homogenized dermis or epidermis; or cell pellets were lysed using RNeasy kit (Qiagen) 
buffers. Due to the volume constraint of the kits, tissue samples had to be split into 
multiple preparations.  Cell lysates were then further homogenized using Shredder 
columns (Qiagen) and RNA isolation continued with RNeasy kit. All of the reagents used 
for RT and PCR were obtained from SuperArray Biosciences, Frederick, MD.  The 
following were added to a 0.2 ml tube where first a genomic DNA elimination step was 
performed; 2 µg RNA in a total volume of 10 µl was heated to 42oC for 5 minutes and 
chilled on ice.  Then, the reverse transcription cocktail was prepared and 10 µl added to 
the RNA;  2 µl RT enzyme mix, 4 µl RT buffer, 1 µl primer and external control mix, 3 µl 
RNase free water.  This mixture was heated 42oC for 15 minutes, 95oC for 5 minutes and 
chilled on ice for experiments, the final volume of cDNA was 20 µl.   qRT-PCR was 
performed using a LightCycler PCR (Roche Scientific, Fishers IN) or StepOneTM Real-Time 
PCR system (Life Technologies (Applied Biosystems, Carlsbad, CA, USA).  Qualification of 
experimental qRT-PCR products was determined by comparison with external control 
qRT-PCR products from β-actin plasmid templates of a known copy number standard 
curve. For this analysis, the endogenous housekeeping gene β-actin was used for 
normalization. The average threshold cycle (CT) of the estrogen receptor of interest was 
subtracted from the average CT of actin. This was then normalized to the average ∆CT 
value for MCF-7 using the formula 2˄ (∆CT of the sample/∆CT of MCF-7).   The fold 
change relative to MCF-7 is reported.  
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Immunofluorescence 
Cells were plated and grown on 22 cm2 glass cover slips. Once the cells reached 
approximately 40-50% confluence, the cover slips were rinsed three times for 5 minutes 
PBS. The cells were fixed with ice cold 100% methanol for 10 minutes. Once the cells are 
fixed, the cover slips were air dried and stored at -20°C until needed. Once ready to 
assay, the samples were thawed at room temperature and rehydrated with five TBS 
washes. In order to permeabilize the cells for antibody uptake, the cover slips were 
treated with 0.2% TritonX-100 in TBS for 5 minutes at room temperature and then 
allowed to dry at room temperature. The cover slips were then blocked with 3% BSA in 
TBS at room temperature for one hour.  The cover slip was transferred to a clean 100 
mm glass petri dish containing a moistened filter paper under Parafilm to create a 
humidified chamber. Primary antibodies to ERα (clone E115 from Millipore) and ERβ  
(SC-8974 from Santa Cruz) were diluted in 3% BSA in TBS in a final volume of 100 µL 
were placed onto the cover slips. The covered petri dish was then incubated for 1 hour 
at room temperature. After the incubation was complete, the cover slips were washed 
three times for ten minutes with TBS. The secondary antibody conjugated to AlexaFluor 
488 which fluoresces green was added to the coverslips and incubated for 30 minutes in 
the dark. The cover slips were then washed three times with TBS, edges were blotted 
dry, and then were mounted to a slide with Fluoromount G. Images were taken with the 
Eclipse 80i microscope with Intensilight Epifluorescence with consistent magnification, 
exposure, and aperture settings.   Exposure time was gated from MCF-7 cell images as 
the positive control.  
Senescence-Associated β-galactosidase assays 
Keratinocytes were seeded at 3.0 x 105 cells per 60 mm dish and grown to 60% 
confluence. One hour following the treatments the cells were irradiated with 0 or 100 
J/m2 of UVB. Seventy two hours later the cells were washed twice with phosphate-
buffered saline and fixed with 2% formaldehyde/0.2% glutaraldehyde at room 
temperature for 10 min. After two additional washes with phosphate-buffered saline, 
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2ml of staining solution (150mM sodium chloride, 25.2mM sodium phosphate dibasic, 
7.36mM citric acid, 5mM potassium ferricyanide, 5mM potassium ferrocyanide, 2mM 
magnesium chloride and 1 ng/ml 5-bromo-4-chloro-3-indolyl-b-D-galactoside, pH 6.0) 
(Dimri et al 1995), was added to the cells and the plates were incubated at 37 °C 
overnight. The cells were again washed with phosphate buffered saline and 
photographed by bright field microscopy to count blue cells and phase contrast 
microscopy to count the total number of cells. At least four fields (100X magnification, 
approximately 200–600 cells/field) were counted for each plate of cells; at least two 
plates of cells for each condition (or cell type) were assayed in each experiment. Total 
cells and blue cells were counted.  
Caspase-3 Assay 
Caspase-3 proteolytic activity was measured using a synthetic fluorogenic substrate 
(DEVD-AMC, Alexis Biochemicals, San Diego, CA) as previously described (Lewis et al 
2003a, Lewis et al 2003b). 5 x 105 cells were plated in 60 mm dishes in Complete EpiLife 
media and incubated for 2-3 days to reach ~75% confluence. One hour following 
treatments, the cells were irradiated with 0 or 400 J/m2 of UVB.   Six hours post 
irradiation the cells were harvested. All cells from the plates including floating cells were 
collected and pelleted in PBS. The cell pellets were used immediately or frozen at -20° C.  
Keratinocyte cell pellets were suspended in lysis buffer (50 mM PIPES pH 7.0, 50 mM 
KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM DTT) and subjected to three cycles of freeze/thaw 
at -70°C and 37°C.  Epidermal and cellular debris were removed by centrifugation.  An 
aliquot of the cell lysate was added to a Caspase -3 reaction buffer (100 mM HEPES, 
pH7.5, 10% sucrose, 0.1% CHAPS, 10 mM DTT, 0.1 mg/ml bovine albumin, and 50 µM 
DEVD-AMC substrate) and incubated at 37°C for 1 hour.  Release of the fluorescent AMC 
moiety was measured using a Hitachi F2000 spectrophotometer (excitation, 380 nm; 
emission, 460 nm).  The fluorescent intensity was converted to pmoles of AMC by 
comparison to the fluorescent intensity of standards of AMC (7-amino-4-
methylcoumarin; Molecular Probes, Eugene, OR). The specific activity of Caspase- 3 in 
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cell lysates was then determined after the total protein concentration of the cell lysates 
was measured (Bio-Rad Protein Assay Reagent).  
Statistical Methods 
Statistical significance was determined using the t-test and p value threshold of < 0.05. 
Geometric mean analysis was used where noted.  When there are two distinct groups of 
numbers with vastly different absolute values, utilizing geometric means allows for 
more accurate representation of the data. The geometric mean is always less than or 
equal to the arithmetic mean thus is a more conservative representation of the data and 
often used when all values being analyzed are positive.   
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RESULTS 
ER expression in human skin cells in vitro and in vivo 
Several cell lines including primary keratinocytes and primary fibroblasts along with 
epidermis and dermis tissue samples were analyzed by qRT-PCR for the presence of 
ESR1 (ERα) and ESR2 (ERβ) gene expression. The skin cell models used for the 
experiments determining the response to UVB after estrogen treatment were obtained 
from males, NHK and nTERT. In Table 1, each experimental cell line source is described 
by age and gender along with any known karyotype. As previously reported by others 
(Ohata et al 2008, Pelletier & Ren 2004, Thornton et al 2003), male skin does contain 
estrogen receptors (Figure 1).  Both keratinocytes and fibroblasts have low levels of ERα 
message when compared to MCF-7 breast cancer positive control cells yet more than 
the negative breast cancer cell line, MDA-MB-231 (Figure 1A). In contrast, the levels of 
ERβ in keratinocytes and fibroblasts are similar to MCF-7 levels and MDA-MB-231 
(Figure 1B).   
The same trend held true when examining tissue sections of the epidermis and dermis. 
Low levels of ESR1 (Figure A) and comparable levels of ESR2 (Figure 1B) were detected 
in both tissues when compared to MCF-7 positive cells. To determine location and 
expression of estrogen receptor protein, immunofluorescence (IF) was used in 
keratinocytes.  MCF-7 cells were used as positive controls and were used to gate the 
exposures with the same magnification. ERα was not detectable in the keratinocytes 
with IF (Figure 2 Top Row). In contrast, ERβ was detectable across keratinocytes and in 
both controls (Figure 2 Bottom panel). ERβ is most prevalent in the peri-nuclear space 
and diffuse throughout the cytosol in the skin cells but restricted to the peri-nuclear 
space in the breast cancer control line, MCF-7. This could be indicative of differences in 
mechanisms of action as the ERβ residing in the cytosol is more likely to be involved in 
signaling cascade pathways than transcription regulation.   
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E2-treatment does not influence UVB induced senescence in keratinocytes 
Keratinocytes use senescence as a tumor-evasion mechanism in response to 
intermediate doses of UVB. The cells continue to function biologically and maintain the 
barrier of the skin but cannot divide and proliferate.  We examined if E2-treatment 
would change the normal senescence response of keratinocytes to intermediate levels 
of UVB. There are 2 outcomes for exposure intermediate dose levels of UVB: 1) DNA 
damage is repaired and the cell continues proliferating, or 2) DNA repair is incomplete 
and mitotic arrest occurs, called senescence. Cells that have undergone senescence 
endogenously produce senescence-associated beta-galactosidase which when incubated 
with D-galactoside produces a blue color. Cells that have senesced can be imaged and 
counted as a percentage of total cells in a field. Both primary keratinocytes and the 
immortalized nTERT were treated with E2 1 hour prior to irradiation with UVB.  
Treatment with E2 was maintained until fixation and staining 72 hours after irradiation.  
The images in Figure 3 (Panel A and B) are examples from an experiment to illustrate 
the level of β-gal staining. The data represent a summary of three individual 
experiments with nTERT and five individual experiments with normal human 
keratinocytes. Within each experiment, there were 2 replicate plates per condition with 
4 independent fields counted per plate. There were no statistically significant 
differences seen in either cell model. The nTERT cells had higher percentage of 
senescent cells after exposure to 100 J/m2 UVB in the absence of E2-treatment with 45% 
compared to the 25% seen with normal human keratinocytes (Figure 3 Panel C and D). 
The nTERT cells do senesce after exposure to UVB, thought no difference is detected 
when treated with E2.  
E2-treatment did not increase UVB induced apoptosis in NHK but suggests an increase 
in nTERT cells  
Caspase- 3, a cysteine aspartic acid specific protease, activity was used to measure 
apoptosis before and after treatment with UVB. Programmed cell death is part of the 
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normal processes such as cell removal, embryonic development, and immune system 
function.  Kerr et al first introduced the term apoptosis in 1972 (Kerr et al 1972). There 
are other caspase independent pathways but here we focused on caspase-dependent 
induction of apoptosis. Various stimuli such as radiation, toxins, hypoxia, hyperthermia, 
viral infections, and free radicals can induce cellular changes culminating in 
mitochondria release of cytochrome- c. Cytochrome c binds  APAF-1 and pro-caspase 9 
to form the apoptosome which initiates the intrinsic caspase dependent apoptosis 
pathway. Procaspase-9 is cleaved to form active caspase 9 which then activates caspase 
3. With high levels of UVB exposure, there should be a large increase in caspase 3 levels 
to indicate apoptosis induction resulting from the extensive DNA damage inflicted by 
the UVB.   Here we used 400 (J/m2) to induce apoptosis.  NHK or nTERT cells were 
seeded and treated with or without E2 then exposed to 400 J/m2 UVB. The cells were 
harvested approximately 6 hours after irradiation.  Routinely, experiments in our lab 
yield around 1200 (pmoles/hr/ug protein) of caspase 3 specific activity when NHK are 
exposed to 400 (J/m2) of UVB. We did not see that in these experiments with normal 
human keratinocytes as they had a very low response to UVB, around 150 
(pmoles/hr/ug protein) (Figure 4, Panel A). There was not a significant difference 
between the NHK cells treated with E2 and the control cells before or after treatment 
with UVB.  For the nTERT cells when data from all experiments were combined (Figure 4 
Panel B), no significant effect upon UV-induced apoptosis was seen with E2-treatment. If 
each subset is analyzed individually, a significant difference was not seen between the 
E2-treated cells and the control cells after UVB-treatment in the last 4 experiments or in 
the first 4 experiments, p = 0.06 and 0.09 (Figure 4, Panels C and D, respectively).   The 
lower values in the first 4 experiments were consistent with the values seen with the 
NHK experiments. When all values were combined and averaged, the effect was masked 
due to the great absolute difference in the values; Figure 4 Panel B. Using the statistical 
method of geometric means allows 2 distinct groups to maintain the modulation with in 
the groups. When using geometric means, E2-treatment statistically significantly 
increased UVB-induced apoptosis (Figure 4 Panel E). 
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E2 -treatment in the absence of insulin did not increase UVB-induced apoptosis in NHK 
cells 
Activation of insulin growth factor (IGF-1R) in keratinocytes protects cells from UVB- 
induced apoptosis (Lewis et al 2008) by inducing senescence. In Figure 5, insulin was 
removed from the media to examine if E2-treatment would reduce apoptosis. As an 
activated estrogen receptor has been known to activate the IGF1R pathway in other 
tissues (Karl et al 2005), maybe E2-treatment could signal through the IGF1R and trigger 
the protection from apoptosis. The plates without insulin, the non-activated IGF-1R, had 
higher levels of apoptosis compared to the complete media controls (Figure 5 Panel B vs 
Panel A) which confirms the need for activated IGF1R for decreased apoptosis in NHK. 
E2-treatment showed a trend in decreasing the apoptosis with and without UVB-
treatment in the absence of insulin, but this was not statistically significant as the p 
values were 0.34 and 0.56 respectively. These are a compilation of 3 separate 
experiments with 2 replicates per data point. This may suggest that there is some 
inhibition of the IGF1R pathway instead of activation with E2 exposures.  
E2-treatment of Normal Human Fibroblast does not change the UVB-induced apoptosis 
in nTERT keratinocytes exposed to UVB 
Fibroblasts are the primary cells of the dermis, the supporting layer of the skin providing 
tensile strength, and nutrients, which influence keratinocytes by secreting factors into 
the extracellular matrix/microenvironment. To examine if estrogen treatment and 
signaling is acting through fibroblasts to change the microenvironment of the 
keratinocytes, growth factor deprived media was conditioned by NHF for 48 hr in the 
presence or absence of E2.  This conditioned media was then placed on approximately 
70% confluent 60 mm dishes containing nTERT keratinocytes approximately 14 hours 
prior to irradiation with UVB.  Cells were harvested approximately 6 hours after 
irradiation. Figure 6 is compilation of 7 individual experiments.  Keratinocytes do not 
produce IGF-1 thus it is supplied by neighboring fibroblasts. Potential E2-signaling could 
increase the IGF-1 produced by the fibroblasts thus activating the IGF-1R in 
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keratinocytes and protecting the keratinocytes from apoptosis. There was no difference 
seen in the conditioned media with or without E2 (Figure 6).  
Proliferation after UVB irradiation was not effected by treatment with E2 in NHK or 
nTERT cells. 
Traditional proliferation or time-course cell count experiments using phenol red free 
media were not successful as the cells did not exhibit the expected doubling times and 
stopped dividing early (data not shown).  Total cell counts from other experiments, such 
as the senescence-associated β-galactosidase assay, could be used instead as an 
alternative way to assess the proliferation/apoptosis balance with E2-treatment.  We 
used the total cell counts from the senescence analysis to determine the net effect on 
cell growth. The percent total cells relative to the complete media control were 
calculated for each condition of UVB exposure. This was then compiled and averaged 
across the multiple experiments as shown in Figure 7. In Panel A, NHK cells treated with 
E2 yielded similar cell counts to the control untreated cells regardless of UVB treatment 
(p values of 0.97 and 0.21, respectively).  E2-treatment decreased the number of nTERT 
cells without exposure to UVB (Figure 7 Panel B, p=0.0001). This coincides with the 
increased senescence seen in the untreated nTERT cells compared to the untreated NHK 
cells after irradiation (Figure 3 Panels C and D).  
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TABLES 
 
 
 
Table 1: Skin and Breast Cell Line Descriptions 
 
 
 
 
 
 
 
 
 
 
Cell line Description Age Gender Known Characteristics Reference
NHK normal human 
keratinocyte
neonatal 
(newborn)
male
n-TERT
immortalized 
human epidermal 
keratinocyte
neonatal 
(new born)
male hTERT, loss of p16INK4, p53 +/+ 
Dickson et 
al
LiF-TERT
immortalized oral 
mucosal 
keratinocytes
adult (60 yo) female hTERT, p53 +/- Dickson et 
al
NHF normal human 
fibroblasts
neonatal 
(newborn)
male
MCF-7
ERα (+) epidermal 
breast cancer cell 
line
adult (69 yo) female
Express WNT7B, estrogen receptor alpha, IGFBP2, IGFBP4, 
IGFBP5. Growth can be inhibited by TNFalpha. Antiestrogens 
modulate the expression of IGFBP. 
ATCC
MDA-MB_231
ERα (-) epidermal 
breast cancer cell 
line
adult (51 yo) female Express WNT7B, epidermal growth factor receptor, TGF alpha 
receptor. 
ATCC
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FIGURES 
A. 
 
B. 
 
Figure 1: ERα and ERβ message are expressed in keratinocyte cell lines and the skin tissue samples. 
Quantitative PCR analysis of ESR1 (ERα (A)) and ESR2 (ERβ (B)) mRNA isolated from cell lines and tissue 
samples normalized to actin expression.  ∆∆CT was calculated by subtracting the CT of the gene of interest 
from CT of actin relative to MCF-7 breast cancer cell lines.  The fold change was calculated using the 
formula: 2˄ (∆CT of the sample/∆CT of MCF-7). The data represent at least 3 individual experiments with 
each sample run for each gene in duplicate.  ERα is shown in panel A and ERβ is shown in Panel B. Due to 
the vast difference in expression levels, the axis in Panel A is truncated to 0.20. The value for MCF-7 in 
both panels is 1.   
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Figure 2: ERβ protein is detected in MCF-7, NHK, nTERT, and LifTERT cells but ERα protein is only 
detected in the MCF-7 cells.  Cells were grown on glass coverslips, fixed, and permeabilized. Overnight 
incubation allowed for primary antibodies to associate with the estrogen receptors. Secondary antibodies 
conjugated with Alexa Fluor 488 were used to detect and visualize the protein. Exposure time was gated 
on the positive control, MCF-7 cells. Magnification and aperture settings were consistent for all images.   
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A. 
 
B. 
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C.        D 
 
Figure 3: E2-treatment of NHK and nTERT cells did not change UVB-induced senescence.  Normal human 
keratinocytes (A) or nTERT cells (B) were untreated or treated with 1 nM E2.  One hour following the 
treatments the cells were irradiated with 0 or 400 J/m2 of UVB.  Seventy two hours post irradiation cells 
were fixed and stained overnight with beta galactoside to detect Senescence-Associated Beta 
Galactosidase Activity resulting in a blue colored cell. Cells were imaged using bright field microscopy at 
100X magnification.  At least four fields (100X magnification, approximately 200–600 cells/field) were 
counted for each plate of cells; at least two plates of cells for each condition (or cell type) were assayed in 
each experiment. Total cells and blue cells were counted. The error bars represent the standard deviation. 
The data represent five independent assays for NHK (C) and three independent assays for nTERT (D).   
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A.                            B. 
 
C.                                                                        D.  
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E. 
 
Figure 4: Apoptosis in response to UVB is not affected with E2-treatment of NHK cells but is increased 
with E2-treatment of nTERT cells. Normal human keratinocytes (A) or nTERT cells (B) were untreated or 
treated with 1 nM E2.  One hour following the treatments the cells were irradiated with 0 or 400 J/m
2 of 
UVB.  Six hours post irradiation cells were harvested and caspase-3 activity was detected.  Error bars 
indicate the standard deviation. The data represent three independent assays for NHK (A) and eight 
independent assays for nTERT (B).  The last four nTERT experiments (C) yielded higher absolute results 
compared to the first 4 nTERT experiments (D).  When analyzed by subgroups, the nTERT experiments did 
not show a significant difference between the E2-treated cells and the control cells after UVB treatment  
in last 4 experiments group or in the first 4 experiments group (p= 0.06 and 0.09). Using the statistical 
method of geometric means allows 2 distinct groups to maintain the modulation with in the groups (E).  
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A.       B. 
 
Figure 5: UVB-induced apoptosis in NHK cells is not changed by treatment with E2 in the presence or 
absence of insulin. Eighteen to twenty four hours prior to irradiation, keratinocytes were treated with 
complete media or media without insulin. One hour following the treatments with 1 nM E2, the cells were 
irradiated with 0 or 400 J/m2 of UVB.  Six hours post irradiation cells were harvested and caspase-3 
activity was detected.  Error bars indicate the standard deviation. The data represent three independent 
assays. All conditions were run within an experiment. Panel A is the same data represented in Figure 4A.  
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Figure 6: E2-treatment of NHF cells and the resulting conditioned media does not change the UVB 
response of nTERT cells. Growth Factor Deprived Media was conditioned by incubation with NHF-543 for 
48 hours with and without 10 nM E2.  Plates with ~75% confluent with nTERT cells were treated with 
either conditioned media or growth deprived media with and without 10 nM E2 for 15 hours prior to 
irradiation with 0 or 400 J/m2. Cells were harvested 6 hours post irradiation and caspase-3 activity was 
detected. Error bars indicate the standard deviation.  The data represent seven independent assays. 
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Figure 7: Proliferation is decreased in nTERT cells treated with E2 regardless of UVB exposure but did not 
affect NHK cells.  Total cell numbers from the SA-beta gal experiments were used.  Normal human 
keratinocytes (A) or nTERT cells (B) were untreated or treated with 1 nM E2.  One hour following the 
treatments the cells were irradiated with 0 or 400 J/m2 of UVB.  Two to three days post irradiation cells 
were fixed. Cells were imaged using bright field microscopy at 100X magnification.  At least four fields 
(100X magnification, approximately 200–600 cells/field) were counted for each plate of cells; at least two 
plates of cells for each condition (or cell type) were assayed in each experiment. Total cells were counted. 
The error bars represent the standard deviation. The data represent five independent assays for NHK (A) 
and three independent assays for nTERT (B).   
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DISCUSSION 
Understanding the multiple factors that contribute to protection against UVB-induced 
skin cancer can lead to the development of better preventative measures and 
treatments. There has been an explosion of data regarding the signaling pathways 
involved in the induction of skin cancer, and those pathways have found be to more 
complex and intertwined than initially understood. This analysis may provide one small 
piece of the puzzle to further elucidate how estrogen receptor signaling plays a role in 
cancers other than breast, ovarian, and uterine cancers usually associated with estrogen 
receptor status. 
To see protection from UVB, the cells would need to prevent one or more of the many 
hallmarks of cancer. In this study we focused on the axis of cell growth, senescence, and 
apoptosis. There is a fine balance that occurs within any tissue to maintain tissue health. 
To provide protection, there would be an expectation of increased apoptosis to remove 
the aberrantly damaged cells. Senescence would increase which would result in 
stopping overall tumor growth yet retaining the intact cells where they can interact with 
the microenvironment. Proliferation would decrease or remain constant to reduce or 
stabilize tumor growth.  
Skin provides unique challenges being the largest organ in the human body. Extensive 
apoptosis can compromise the barrier function of the skin which clinically manifests as 
Steven-Johnsons Syndrome, mucositis, pruritus, and rash. Increased senescence would 
maintain the barrier function but have the potential to flood the microenvironment with 
potentially wanted and unwanted signals. Decreased proliferation would impact the 
turnover rate in the skin layers and could negatively impact the skin’s ability to respond 
to physical damage as proliferation would be needed in wound healing and replacement 
of cells removed during apoptosis.  
The elucidation of cancer has become more complex with the vast amount of data 
generated over the past several years. There are several general hallmarks of cancer as 
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discussed by Hanahan and Weinberg and in addition pathways have been further 
defined. These pathways are not simple linear lines as once thought. Now, they form a 
complex web intertwined merging and diverging causing complexity to be compounded.  
Using in vitro cell-based assays is a way to simplify the noise by controlling the 
conditions. To clearly examine estrogen influence on this system, the ideal conditions 
would be to complete the experiments without any endogenous estrogen or estrogen-
like compounds present in the media. Phenol red is a known phytoestrogen and can 
signal through the estrogen receptor. We attempted to use phenol red free media to 
complete the initial proliferation experiments but the cells did not grow as expected. 
Due to the presence of baseline estrogen, the interpretation is more complex. Counting 
total cell numbers is not a pure measurement of proliferation as the cell number total is 
affected by proliferation, apoptosis, and senescence. Maybe the influence of E2-
treatment on proliferation could be assessed in a different way using a proliferation 
marker such as Ki67 or a viability assay such as MTT. As another alternative, the cells 
could be seeded in normal media and allowed to attach. Once attached, the normal 
media could be withdrawn and replaced with different conditions of interest such as 
phenol red free media, phenol red media plus E2, complete media, and complete media 
plus E2.  Subsequent experiments should include DPN, diarylpropionitrile which is an 
ERβ selective agonist;   PPT, propyl pyrazole triol which is an ERα selective agonist; MPP 
dihydrochloride, 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-
1H-pyrazole dihydrochloride which is an ERα selective antagonist; and PHTPP, 4-[2-
Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol which is an ERβ 
selective antagonist. This would discern which receptor subtype is contributing to the 
response if any. 
Signaling through the estrogen receptor is rapid and then the receptor is degraded. 
Depending on the flux of the receptor and the timing of the sampling a rapid effect is 
difficult to characterize.  The time points used for the assays were standard for our lab 
which we use to analyze IGF1R signaling.  Completing a time course to discern the 
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optimal collection time for maximum signal for estrogen receptor pathway and being 
able to complete the experiments in a truly estrogen free environment using phenol red 
free media would have been informative. Unfortunately, the cells did not grow or 
behave normally in the phenol red free media.  In addition, potentially adding a 
proteasome inhibitor such as MG132 could be added to stabilize the effects. More 
specific and robust antibodies to ERα and ERβ have been development by Cell Signaling 
since this analysis. Better tools and other more stable read-outs of estrogen receptor 
activity could have been used to assess E2 transcriptional effects on cell cycle 
progression and evading apoptosis by analyzing additional downstream targets such as 
Cyclin D1 and Bcl2 measured via PCR and Western Blot.   
Though the majority of the experiments were inconclusive, there were still some 
interesting findings with the nTERT cells. These cells have been transformed with active 
telomerase into an immortal cell line and have also acquired the loss of p16INK4.  The 
nTERT cells do not produce p16 thus cannot induce senescence via the retinoblastoma 
(Rb) pathway. p16 binds cyclin dependent kinase 4/6 (CDK4/6) preventing the kinase 
from phosphorylating Rb which is associated with E2F1 transcription factor.  When Rb is 
phosphorylated, it releases E2F1 that translocates to the nucleus and induces 
transcription of cell cycle genes causing progression from G1 to S phase (Rayess et al 
2012). nTERT cells still do senescence. Maybe an activated ER acts within the p16/Rb 
pathway, possibly blocking CDK4/6 activity or another player in the signal transduction 
cascade.   
There are additional pathways to induce senescence.  nTERT cell still to our knowledge 
have functional p53. p53 and a functional IGF1R are required for senescence in 
keratinocytes (Lewis et al 2008). IGF1R once activated phosphorylates p53 at serine 46. 
It is possible that E2 induces expression of ATM, ATR, or CHK1/2 upstream of p53. To 
further evaluate this question, it would be interesting to compare the response of nTERT 
with presumably intact WTp53 and LifTERT cells that were heterozygous for p53, and if 
possible a third keratinocyte cell line with the total loss of p53. In addition, using 
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receptor specific agonists such as DPN or PPT along with an ERα antagonist would 
confirm the response was specific to estrogen signaling and elucidate which subtype(s) 
contribute to the effect.   Alternatively, activated ER may trigger senescence through 
transcriptional regulation modulating p53 or its target genes. Possibly, ER signaling via 
E2 may provide another way outside of preventing phosphorylation of Rb or induction of 
p53 genes and activity to induce senescence, a back-up mechanism.  
Caspase 3 activity was increased in the nTERT cells treated with E2 compared to the 
nTERT complete media control cells indicating an increase in apoptosis. This did not hold 
true when the cells were exposed to high levels of UVB. Estrogen treatment increased 
apoptosis regardless of the exposure to UVB. This may suggest that there is some 
inhibition of the IGF1R pathway instead of activation with E2 exposures. We tested this 
hypothesis with NHK cells but not with nTERT cells.  Though there was no effect in the 
NHK cells, it would be informative to test the response of nTERT cells in the presence 
and absence of insulin to assess if IGF1R activation is playing a role in the response. As 
an added control, one experimental group should have IGF1R silenced either through 
siRNA or an IGF1R inhibitor such as PPP. The conditioned media experiments do not 
suggest that the protection is being provided through estrogen signaling in fibroblasts. 
Maybe regulatory proteins such as IGFBP proteins which are known to be controlled by 
estrogen receptor signaling (Qin et al 1999)are being increased within keratinocytes and 
are playing a role.  
Interestingly, other groups have recently begun exploring the modulation of estrogen 
receptors in skin. Chaudhary et al (Chaudhary et al 2014) reported on the effects of an 
estrogen beta specific agonist on UVB response in skin. When nude mice were treated 
topically with the ERβ agonist, ERB-041, and exposed to UVB, the tumors were delayed 
in onset, 80% decrease in tumor size, and a 60% decrease in the number of tumors. 
These results are very similar to the effects seen in the female mice compared to the 
male mice in the Thomas-Ahner paper (Thomas-Ahner et al 2007). They also 
demonstrated that activation of the ERβ receptor decreased pro-inflammatory signaling, 
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infiltration of the neutrophils, and myeloperoxidase activity within the tumors. In 
addition, they examined the effect on WNT signaling in various cell lines including HaCaT 
cells (an immortalized keratinocyte), A431 (human epidermoid carcinoma), SCC13 (a 
squamous cell carcinoma). Treatment with ERB-041 induced G1 cell cycle arrest, and 
inhibited colony formation through the WNT/beta catenin pathway.  This information is 
compelling but should be used with caution as HaCaT cells do not act as normal 
keratinocytes due to the aberrant NFκB activity (Lewis et al 2006). 
Another group examined estrogen beta signaling in relation to Notch which is decreased 
in SCC. Increased ERβ or treatment with an ERβ agonist decreased proliferation, 
increased Notch 1 expression, and squamous differentiation in vitro and in murine 
xenografts (Brooks et al 2014). They also suggest that ERβ is required for PolII 
progression on the NOTCH1 gene as without ERβ replication is stopped. Notch is a direct 
target of p53, which is a reoccurring player. Maybe p53 is a switch for deploying the 
estrogen signal. 
Estrogen receptor signaling in skin cancer is an emerging field. The actions of ERβ have 
been found to be vastly different than the proliferation induction through ERα  in 
breast, and ovarian cancer cells. We examined the effect of E2-treatment on 
proliferation, senescence, and apoptosis in keratinocytes. Though not conclusive, the 
decreased proliferation in the nTERT and the difficulty growing the cells in the absence 
of estrogen suggested there is an effect on keratinocyte survival with E2-treatment. 
nTERT also demonstrated a higher rate of senescence after E2-treatment without 
exposure to UV suggesting that E2 may be providing a back-up mechanism for p16 and 
inhibiting Rb phosphorylation or enabling phosphorylation of p53 at Ser-46 to induce 
senescence. Also, the treatment of nTERT with E2 increased the UVB-induced apoptosis. 
This suggests that replicative immorality can be reduced through the treatment with E2.  
We explored the possibility of estrogen receptor signaling counteracting a few of the 
hallmarks of cancer:  resisting cell death through induction of apoptosis and sustaining 
proliferative signaling through senescence. Oberyszyn et al explored the effect of 
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estrogen signaling on NMSC through the axis of immune response in skin (Thomas-
Ahner et al 2007).  There are still many other facets of NMSC and estrogen signaling to 
explore such as angiogenesis, EMT, and metabolism. Estrogen and the estrogen 
receptor seem to be providing a safety net that is not always needed but present. It will 
be interesting as the field evolves exploring the triggers for estrogen receptor signaling 
involvement, and if it involves a balance of the receptor subtypes. Topical treatment of 
NMSC with ERB-041 is just the beginning for patients to potentially benefit by 
modulating the estrogen receptors in skin.   
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